Breaking Down the Barriers to Precision Cancer Nanomedicine

Nanomedicine offers unique advantages in treating human cancers. However, physiological and pathological barriers within normal and disease tissues, which are highly variable among individuals, often hinder its effectiveness. The body possesses specific innate responses to nanoparticles (NPs), which...

Full description

Saved in:
Bibliographic Details
Published in:Trends in biotechnology (Regular ed.) 2017-02, Vol.35 (2), p.159-171
Main Authors: von Roemeling, Christina, Jiang, Wen, Chan, Charles K, Weissman, Irving L, Kim, Betty Y.S
Format: Article
Language:English
Subjects:
Animals
Bladder cancer
blood–brain barrier
Breast cancer
Cancer therapies
Colorectal cancer
Cytotoxicity
Design
drug delivery
Head & neck cancer
Humans
Immunity, Innate - drug effects
Immunity, Innate - immunology
Immunotherapy - methods
Internal Medicine
Leukemia
Ligands
Liver cancer
Lung cancer
Lymphoma
Metastasis
mononuclear phagocyte system
Multiple myeloma
nanomedicine
nanoparticles
Nanoparticles - chemistry
Nanoparticles - therapeutic use
Neoplasms - drug therapy
Neoplasms - immunology
opsonization
Ovarian cancer
Pancreatic cancer
Pharmaceutical industry
Physiology
Polyethylene glycol
Precision Medicine - methods
Proteins
Surface chemistry
Tumor necrosis factor-TNF
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanomedicine offers unique advantages in treating human cancers. However, physiological and pathological barriers within normal and disease tissues, which are highly variable among individuals, often hinder its effectiveness. The body possesses specific innate responses to nanoparticles (NPs), which when combined with unique pathophysiological signatures in the tumor microenvironment, can severely limit the utility of nanomedicine in the oncological setting. Furthermore, with the successes of cancer immunotherapies, understanding nanoimmune interactions and developing immune-smart cancer nanomedicine that can take advantage of the body's immune functions will increasingly become clinically relevant. Therefore, a better understanding of the important native and acquired biological processes that dictate the fate of nanomedicine is integral to developing more effective individualized platforms for treating cancer patients.
ISSN:0167-7799
1879-3096
DOI:10.1016/j.tibtech.2016.07.006